Supportive Care in Oncology-Significant growth opportunities in new supportive care indications

Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal therapies and novel molecular targeted therapies do not exist without some toxicity, these are not as severe as those associated with chemotherapy.

The oncology supportive care market is forecast to undergo slightly positive growth at a CAGR of 0.6%, from a seven-market sales total of $13,763m in 2006 to $14,679m in 2016. This low level of growth is largely due to an increasing level of patent expiry and generic competition, including the impending launch of biosimilars in the EU.

The erythropoietins class has come under increasing levels of scrutiny of late due to emerging doubts over safety of these products. As a result the FDA and EMEA are recommending more restrictive conditions for use and increased monitoring of patients. It is expected that sales of these products will suffer as a result of these restrictions.

Any significant future growth in the oncology supportive care market will likely come from product development in new indications, such as EGFR-inhibitor associated skin rash. However, given the early-phase of clinical development for such products, it will be some time before any impact is made and true future potential can be determined.

Read more...

• Top 20 Therapy Cancer Brands (07/10/2008)
• Cancer epidemic looming in Asia (27/05/2008)
• Pricing and Reimbursement in Oncology (27/05/2008)

• Irritable Bowel Syndrome (21/05/2008)
• Monoclonal Antibodies (21/05/2008)
• Depression (21/05/2008)
• Insomnia (21/05/2008)
• Multiple Sclerosis (21/05/2008)
• Osteoporosis (21/05/2008)
• Monoclonal Antibodies (20/05/2008)
• Top 20 Cancer Therapy Brands (20/05/2008)
• Brain Cancer (20/05/2008)

---